Literatur
- 1
Bellomo R, Chapman M, Finfer S. et al .
Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled
randomised trial. Australian and New Zealand Intensive Care Society (ANZICS)
Clinical Trials Group.
Lancet.
2000;
356
2139-2143
- 2
Bertrand M E, Simoons M L, Fox K A. et al .
Management of acute coronary syndromes in patients presenting without persistent
ST-segment elevation.
Eur Heart J.
2002;
23
1809-1840
- 3
Chan A W, Chew D P, Bhatt D L. et al .
Long-term mortality benefit with the combination of stents and abciximab for
cardiogenic shock complicating acute myocardial infarction.
Am J Cardiol.
2002;
89
132-136
- 4
Chen E W, Canto J G, Parsons L S. et al .
Relation between hospital intra-aortic balloon counterpulsation volume and mortality
in acute myocardial infarction complicated by cardiogenic shock.
Circulation.
2003;
108
951-957
- 5
Goldberg R J, Samad N A, Yarzebski J. et al .
Temporal trends in cardiogenic shock complicating acute myocardial infraction.
N Engl J Med.
1999;
340
1162-1168
- 6
Hamm C W.
Leitlinien: Akutes Koronarsyndrom (ACS). Teil 1: ACS ohne persistierende ST-Hebung.
Z Kardiol.
2004;
93
72-90
- 7
Hamm C W.
Leitlinien: Akutes Koronarsyndrom (ACS). Teil 2: ACS mit ST-Hebung.
Z Kardiol.
2004;
93
324-341
- 8
Herlitz J, Waagstein F, Lindqvist J. et al .
Effect of metoprolol on the prognosis for patients with suspected acute myocardial
infarction and indirect signs of congestive heart failure (a subgroup analysis
of the Goteborg Metoprolol Trial).
Am J Cardiol.
1997;
80
40J-44J
- 9
Hochman J S, Buller C E, Sleeper L A. et al .
Cardiogenic shock complicating acute myocardial infarction-etiologies, management
and outcome: a report from the SHOCK Trial Registry. Should we emergently revascularize
Occluded Coronaries for cardiogenic shock?.
J Am Coll Cardiol.
2000;
36
1063-1070
- 10
Holzer R, Balzer D, Amin Z. et al .
Transcatheter closure of postinfarction ventricular septal defects using the
new Amplatzer muscular VSD occluder: Results of a US Registry.
Catheter Cardiovasc Interv.
2004;
6
196-201
- 11
Hudson M P, Granger C B, Topol E J. et al .
Early reinfarction after fibrinolysis: experience from the global utilization
of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary
arteries (GUSTO I) and global use of strategies to open occluded coronary arteries
(GUSTO III) trials.
Circulation.
2001;
104
1229-1235
- 12
Neuberg G W, Miller A B, O’Connor C M. et al .
Diuretic resistance predicts mortality in patients with advanced heart failure.
Am Heart J.
2002;
144
31-38
- 13
Sanborn T A, Sleeper L A, Bates E R. et al .
Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their
combination in cardiogenic shock complicating acute myocardial infarction: a
report from the SHOCK Trial Registry. Should we emergently revascularize Occluded
Coronaries for cardiogenic shock?.
J Am Coll Cardiol.
2000;
36
1123-1129
- 14
Spargias K S, Hall A S, Ball S G.
Safety concerns about digoxin after acute myocardial infarction.
Lancet.
1999;
354
391-392
- 15
Van de Werf F, Ardissino D, Betriu A. et al .
Management of acute myocardial infarction in patients presenting with ST-segment
elevation. The Task Force on the Management of Acute Myocardial Infarction of
the European Society of Cardiology.
Eur Heart J.
2003;
24
28-66
Prof. Dr. med. Michael Böhm
Universitätsklinikum des Saarlandes, Innere Medizin III (Kardiologie/Angiologie/Internistische
Intensivmedizin)
Kirrberger Straße
66421 Homburg/Saar
Phone: 06841/1623372
Fax: 06841/1623369
Email: Boehm@Med-In.uni-saarland.de
